INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
Syndax Pharmaceuticals Inc SNDX
News
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
Syndax Announces Participation in November Investor Conferences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
Syndax Says Pulmonary Fibrosis Drug Trial Misses Primary Endpoint
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Announces Participation in September Investor Conferences
Syndax Wins FDA Approval for Leukemia Treatment
United States